Cargando…

Implantable system for treprostinil: a real-world patient experience study

Parenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. However, subcutaneous or intravenous delivery via an external pump places a significant burden on patients. Consequently, the Implantable System for Remodulin© (treprostinil) was developed a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shapiro, Shelley, Bourge, Robert C., Pozella, Patti, Harris, David F., Borg, Erick H., Nelsen, Andrew C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177997/ https://www.ncbi.nlm.nih.gov/pubmed/32363029 http://dx.doi.org/10.1177/2045894020907881

Ejemplares similares

Dosing characteristics of oral treprostinil in real-world clinical practice
por: Balasubramanian, Vijay P., et al.
Publicado: (2018)

Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study
por: Feldman, Jeremy P., et al.
Publicado: (2021)

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting
por: Balasubramanian, Vijay P., et al.
Publicado: (2022)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
por: Chen, Hubert, et al.
Publicado: (2013)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily
por: Shapiro, Shelley, et al.
Publicado: (2021)

A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration
por: Kumar, Parag, et al.
Publicado: (2016)

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
por: Lescano, Adrián, et al.
Publicado: (2022)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies
por: Tonelli, Adriano R., et al.
Publicado: (2020)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
por: Johnson, Shelsey W., et al.
Publicado: (2022)

Effective treatment of malignant atrophic papulosis (Köhlmeier-Degos disease) with treprostinil – early experience
por: Shapiro, Lee S, et al.
Publicado: (2013)

Novel dose–response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations
por: Ramani, Gautam, et al.
Publicado: (2020)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
por: Desole, Susanna, et al.
Publicado: (2018)

Oral treprostinil use in children: a multicenter, observational experience
por: Kanaan, Usama, et al.
Publicado: (2019)

Inhaled treprostinil: a therapeutic review
por: Channick, Richard N, et al.
Publicado: (2012)

Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
por: White, R. James, et al.
Publicado: (2020)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
por: Kingrey, John F., et al.
Publicado: (2023)

Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension—procedural safety and system-related complications
por: Steringer-Mascherbauer, Regina, et al.
Publicado: (2020)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
por: Kurzyna, Marcin, et al.
Publicado: (2017)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation
por: Rahaghi, Franck F., et al.
Publicado: (2017)

Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
por: Coons, James C., et al.
Publicado: (2018)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
por: Kamp, Jan C., et al.
Publicado: (2021)

Treprostinil stimulates the engraftment of haematopoetic stem cells
por: Hussain, Filza, et al.
Publicado: (2011)

Successful management of an inadvertent excessive treprostinil overdose
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2013)

Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
por: Nathan, Steven D., et al.
Publicado: (2021)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation
por: Kazemi, Zahra, et al.
Publicado: (2016)

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
por: Kolb, Martin, et al.
Publicado: (2022)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
por: Gauani, Helena, et al.
Publicado: (2023)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
por: Ivy, D. Dunbar, et al.
Publicado: (2019)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Treprostinil reduces endothelial damage in murine sinusoidal obstruction syndrome
por: Themanns, Madeleine, et al.
Publicado: (2018)

An Event-driven Trial for Oral Treprostinil. Progress but Not the Holy Grail
por: Hill, Nicholas S., et al.
Publicado: (2020)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Design, Development, and Evaluation of Treprostinil Embedded Adhesive Transdermal Patch
por: Alissa, Ibrahim, et al.
Publicado: (2023)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
por: Pugliese, Steven C, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ptlrslh4335qe9kmaej8i9ru4g